AstraZeneca

News

ASCO26: After negative adcomm, AZ builds case for oral SERD

AstraZeneca showcases new data from the SERENA-6 data of camizestrant in breast cancer that it hopes will get FDA's review of the drug back on track.

News

Two packets and two vials of different doses of Imfinzi

ASCO26: AZ triplet makes waves in frontline liver cancer

EMERALD-3 suggests a triplet regimen based on AstraZeneca's Imfinzi and Imjudo could be practice-changing as a frontline hepatocellular carcinoma.

News

ASCO26: Could AL amyloidosis see a new crop of therapies?

Trials of AstraZeneca's anselamimab and Regeneron's Lynozyfic could deliver much-needed new therapeutic options for rare disease AL amyloidosis.

News

Ahead of ASCO data drop, AZ gets key Imfinzi approval

AstraZeneca has claimed another key FDA approval for Imfinzi in bladder cancer, as an add-on to BCG therapy for early non-muscle invasive disease.

News

FDA delays verdict on AZ breast cancer drug

After an advisory committee setback, AstraZeneca has a chance to make the case for its oral SERD camizestrant for breast cancer.

News

Datroway is first TROP2 drug for frontline breast cancer

AZ and Daiichi's Datroway has been cleared by the FDA as first-line treatment for triple-negative breast cancer patients ineligible for immunotherapy.

ASCO26: After negative adcomm, AZ builds case for oral SERD

ASCO26: AZ triplet makes waves in frontline liver cancer

ASCO26: Could AL amyloidosis see a new crop of therapies?

Ahead of ASCO data drop, AZ gets key Imfinzi approval

FDA delays verdict on AZ breast cancer drug

Datroway is first TROP2 drug for frontline breast cancer

ADARx, Trex, and Retension take aim at IPOs

Discover a new era of healthcare panel engagement: Grounded ...

AstraZeneca

Editor's Picks